http://120.24.161.253:5617/index.php?action=history&feed=atom&title=%E5%A4%9A%E5%8F%91%E6%80%A7%E7%A1%AC%E5%8C%96-%E8%8D%AF%E7%89%A9%E6%B2%BB%E7%96%97-%E9%82%A3%E4%BB%96%E7%8F%A0%E5%8D%95%E6%8A%97 2026-05-02T11:35:55Z 本wiki的该页面的版本历史 MediaWiki 1.30.0 http://120.24.161.253:5617/index.php?title=%E5%A4%9A%E5%8F%91%E6%80%A7%E7%A1%AC%E5%8C%96-%E8%8D%AF%E7%89%A9%E6%B2%BB%E7%96%97-%E9%82%A3%E4%BB%96%E7%8F%A0%E5%8D%95%E6%8A%97&diff=2028326&oldid=prev 2026-04-16T04:38:03Z

<p>导入1个版本</p> <table class="diff diff-contentalign-left" data-mw="interface"> <tr style="vertical-align: top;" lang="zh-CN"> <td colspan="1" style="background-color: white; color:black; text-align: center;">←上一版本</td> <td colspan="1" style="background-color: white; color:black; text-align: center;">2026年4月16日 (四) 04:38的版本</td> </tr><tr><td colspan="2" style="text-align: center;" lang="zh-CN"><div class="mw-diff-empty">（没有差异）</div> </td></tr></table>

KGadmin http://120.24.161.253:5617/index.php?title=%E5%A4%9A%E5%8F%91%E6%80%A7%E7%A1%AC%E5%8C%96-%E8%8D%AF%E7%89%A9%E6%B2%BB%E7%96%97-%E9%82%A3%E4%BB%96%E7%8F%A0%E5%8D%95%E6%8A%97&diff=2003132&oldid=prev 2026-04-15T13:14:02Z

<p>导入1个版本</p> <table class="diff diff-contentalign-left" data-mw="interface"> <col class="diff-marker" /> <col class="diff-content" /> <col class="diff-marker" /> <col class="diff-content" /> <tr style="vertical-align: top;" lang="zh-CN"> <td colspan="2" style="background-color: white; color:black; text-align: center;">←上一版本</td> <td colspan="2" style="background-color: white; color:black; text-align: center;">2026年4月15日 (三) 13:14的版本</td> </tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l5" >第5行：</td> <td colspan="2" class="diff-lineno">第5行：</td></tr> <tr><td class='diff-marker'>&#160;</td><td style="background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;"></td><td class='diff-marker'>&#160;</td><td style="background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;"></td></tr> <tr><td class='diff-marker'>&#160;</td><td style="background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;"><div>==来源==</div></td><td class='diff-marker'>&#160;</td><td style="background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;"><div>==来源==</div></td></tr> <tr><td class='diff-marker'>−</td><td style="color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>===<del class="diffchange diffchange-inline">全身型重症肌无力患者异常胸腺microRNA表达谱的初步研究</del>===</div></td><td class='diff-marker'>+</td><td style="color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>===<ins class="diffchange diffchange-inline">多发性硬化治疗措施的临床证据评价===</ins></div></td></tr> <tr><td class='diff-marker'>−</td><td style="color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>[[那他珠单抗]]治疗[[多发性硬化]]<del class="diffchange diffchange-inline">患者6个月后血液中miR一125a一5p的表达下降，表明miR一125a一5p可以在</del>[[那他珠单抗]]治疗[[多发性硬化]]<del class="diffchange diffchange-inline">过程中作为一种可能的评价疗效的指标</del>[<del class="diffchange diffchange-inline">1⋯。</del></div></td><td class='diff-marker'>+</td><td style="color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins class="diffchange diffchange-inline">(2)干扰素-β、醋酸格拉默可以作为[[多发性硬化]]缓解期治疗的一线药物,若无效可以米托恩醌、[[那他珠单抗]]作为二线治疗药物.</ins></div></td></tr> <tr><td colspan="2">&#160;</td><td class='diff-marker'>+</td><td style="color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>&#160;</div></td></tr> <tr><td colspan="2">&#160;</td><td class='diff-marker'>+</td><td style="color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins class="diffchange diffchange-inline">===那他珠单抗治疗多发性硬化研究进展===</ins></div></td></tr> <tr><td colspan="2">&#160;</td><td class='diff-marker'>+</td><td style="color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins class="diffchange diffchange-inline">[[那他珠单抗]]治疗[[多发性硬化]]研究进展</ins></div></td></tr> <tr><td colspan="2">&#160;</td><td class='diff-marker'>+</td><td style="color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>&#160;</div></td></tr> <tr><td colspan="2">&#160;</td><td class='diff-marker'>+</td><td style="color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins class="diffchange diffchange-inline">===那他珠单抗治疗多发性硬化和克罗恩病的安全性及有效性Meta分析</ins>===</div></td></tr> <tr><td colspan="2">&#160;</td><td class='diff-marker'>+</td><td style="color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>[[那他珠单抗]]治疗[[多发性硬化]]<ins class="diffchange diffchange-inline">和克罗恩病的安全性及有效性Meta分析</ins></div></td></tr> <tr><td colspan="2">&#160;</td><td class='diff-marker'>+</td><td style="color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>&#160;</div></td></tr> <tr><td colspan="2">&#160;</td><td class='diff-marker'>+</td><td style="color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins class="diffchange diffchange-inline">===那他珠单抗治疗多发性硬化和克罗恩病的安全性及有效性Meta分析===</ins></div></td></tr> <tr><td colspan="2">&#160;</td><td class='diff-marker'>+</td><td style="color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins class="diffchange diffchange-inline">目的 系统评价</ins>[[那他珠单抗]]治疗[[多发性硬化]]<ins class="diffchange diffchange-inline">(MS)和克罗恩病(CD)的安全性及有效性.</ins></div></td></tr> <tr><td colspan="2">&#160;</td><td class='diff-marker'>+</td><td style="color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>&#160;</div></td></tr> <tr><td colspan="2">&#160;</td><td class='diff-marker'>+</td><td style="color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins class="diffchange diffchange-inline">===从那他珠单抗不良反应处理看生物制剂风险监测——基于严重不良反应报告与相关管理文件的系统评价===</ins></div></td></tr> <tr><td colspan="2">&#160;</td><td class='diff-marker'>+</td><td style="color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins class="diffchange diffchange-inline">鉴于[[那他珠单抗]]其治疗[</ins>[<ins class="diffchange diffchange-inline">多发性硬化]](MS)、克罗恩病(CD)的不可替代性,FDA决定在严密监控下病人仍可用此药.</ins></div></td></tr> </table>

KGadmin http://120.24.161.253:5617/index.php?title=%E5%A4%9A%E5%8F%91%E6%80%A7%E7%A1%AC%E5%8C%96-%E8%8D%AF%E7%89%A9%E6%B2%BB%E7%96%97-%E9%82%A3%E4%BB%96%E7%8F%A0%E5%8D%95%E6%8A%97&diff=2028325&oldid=prev 2026-04-13T13:56:59Z

<p>修改1</p> <table class="diff diff-contentalign-left" data-mw="interface"> <col class="diff-marker" /> <col class="diff-content" /> <col class="diff-marker" /> <col class="diff-content" /> <tr style="vertical-align: top;" lang="zh-CN"> <td colspan="2" style="background-color: white; color:black; text-align: center;">←上一版本</td> <td colspan="2" style="background-color: white; color:black; text-align: center;">2026年4月13日 (一) 13:56的版本</td> </tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l5" >第5行：</td> <td colspan="2" class="diff-lineno">第5行：</td></tr> <tr><td class='diff-marker'>&#160;</td><td style="background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;"></td><td class='diff-marker'>&#160;</td><td style="background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;"></td></tr> <tr><td class='diff-marker'>&#160;</td><td style="background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;"><div>==来源==</div></td><td class='diff-marker'>&#160;</td><td style="background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;"><div>==来源==</div></td></tr> <tr><td class='diff-marker'>−</td><td style="color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>===<del class="diffchange diffchange-inline">多发性硬化治疗措施的临床证据评价===</del></div></td><td class='diff-marker'>+</td><td style="color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>===<ins class="diffchange diffchange-inline">全身型重症肌无力患者异常胸腺microRNA表达谱的初步研究</ins>===</div></td></tr> <tr><td class='diff-marker'>−</td><td style="color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del class="diffchange diffchange-inline">(2)干扰素-β、醋酸格拉默可以作为[[多发性硬化]]缓解期治疗的一线药物,若无效可以米托恩醌、[[那他珠单抗]]作为二线治疗药物.</del></div></td><td class='diff-marker'>+</td><td style="color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>[[那他珠单抗]]治疗[[多发性硬化]]<ins class="diffchange diffchange-inline">患者6个月后血液中miR一125a一5p的表达下降，表明miR一125a一5p可以在</ins>[[那他珠单抗]]治疗[[多发性硬化]]<ins class="diffchange diffchange-inline">过程中作为一种可能的评价疗效的指标</ins>[<ins class="diffchange diffchange-inline">1⋯。</ins></div></td></tr> <tr><td class='diff-marker'>−</td><td style="color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>&#160;</div></td><td colspan="2">&#160;</td></tr> <tr><td class='diff-marker'>−</td><td style="color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del class="diffchange diffchange-inline">===那他珠单抗治疗多发性硬化研究进展===</del></div></td><td colspan="2">&#160;</td></tr> <tr><td class='diff-marker'>−</td><td style="color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del class="diffchange diffchange-inline">[[那他珠单抗]]治疗[[多发性硬化]]研究进展</del></div></td><td colspan="2">&#160;</td></tr> <tr><td class='diff-marker'>−</td><td style="color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>&#160;</div></td><td colspan="2">&#160;</td></tr> <tr><td class='diff-marker'>−</td><td style="color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del class="diffchange diffchange-inline">===那他珠单抗治疗多发性硬化和克罗恩病的安全性及有效性Meta分析</del>===</div></td><td colspan="2">&#160;</td></tr> <tr><td class='diff-marker'>−</td><td style="color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>[[那他珠单抗]]治疗[[多发性硬化]]<del class="diffchange diffchange-inline">和克罗恩病的安全性及有效性Meta分析</del></div></td><td colspan="2">&#160;</td></tr> <tr><td class='diff-marker'>−</td><td style="color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>&#160;</div></td><td colspan="2">&#160;</td></tr> <tr><td class='diff-marker'>−</td><td style="color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del class="diffchange diffchange-inline">===那他珠单抗治疗多发性硬化和克罗恩病的安全性及有效性Meta分析===</del></div></td><td colspan="2">&#160;</td></tr> <tr><td class='diff-marker'>−</td><td style="color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del class="diffchange diffchange-inline">目的 系统评价</del>[[那他珠单抗]]治疗[[多发性硬化]]<del class="diffchange diffchange-inline">(MS)和克罗恩病(CD)的安全性及有效性.</del></div></td><td colspan="2">&#160;</td></tr> <tr><td class='diff-marker'>−</td><td style="color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>&#160;</div></td><td colspan="2">&#160;</td></tr> <tr><td class='diff-marker'>−</td><td style="color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del class="diffchange diffchange-inline">===从那他珠单抗不良反应处理看生物制剂风险监测——基于严重不良反应报告与相关管理文件的系统评价===</del></div></td><td colspan="2">&#160;</td></tr> <tr><td class='diff-marker'>−</td><td style="color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del class="diffchange diffchange-inline">鉴于[[那他珠单抗]]其治疗[</del>[<del class="diffchange diffchange-inline">多发性硬化]](MS)、克罗恩病(CD)的不可替代性,FDA决定在严密监控下病人仍可用此药.</del></div></td><td colspan="2">&#160;</td></tr> </table>

Admin http://120.24.161.253:5617/index.php?title=%E5%A4%9A%E5%8F%91%E6%80%A7%E7%A1%AC%E5%8C%96-%E8%8D%AF%E7%89%A9%E6%B2%BB%E7%96%97-%E9%82%A3%E4%BB%96%E7%8F%A0%E5%8D%95%E6%8A%97&diff=2003131&oldid=prev 2026-04-13T13:56:59Z

<p>修改1</p> <p><b>新页面</b></p><div>主实体：[[多发性硬化]]，关系：[[药物治疗]] ，尾实体：[[那他珠单抗]]<br /> <br /> ==关系介绍==<br /> 待补充<br /> <br /> ==来源==<br /> ===多发性硬化治疗措施的临床证据评价===<br /> (2)干扰素-β、醋酸格拉默可以作为[[多发性硬化]]缓解期治疗的一线药物,若无效可以米托恩醌、[[那他珠单抗]]作为二线治疗药物.<br /> <br /> ===那他珠单抗治疗多发性硬化研究进展===<br /> [[那他珠单抗]]治疗[[多发性硬化]]研究进展<br /> <br /> ===那他珠单抗治疗多发性硬化和克罗恩病的安全性及有效性Meta分析===<br /> [[那他珠单抗]]治疗[[多发性硬化]]和克罗恩病的安全性及有效性Meta分析<br /> <br /> ===那他珠单抗治疗多发性硬化和克罗恩病的安全性及有效性Meta分析===<br /> 目的 系统评价[[那他珠单抗]]治疗[[多发性硬化]](MS)和克罗恩病(CD)的安全性及有效性.<br /> <br /> ===从那他珠单抗不良反应处理看生物制剂风险监测——基于严重不良反应报告与相关管理文件的系统评价===<br /> 鉴于[[那他珠单抗]]其治疗[[多发性硬化]](MS)、克罗恩病(CD)的不可替代性,FDA决定在严密监控下病人仍可用此药.</div>

Admin